endofocusFOCUS ЭндокринологияFOCUS. Endocrinology2713-01772713-0185ООО "Издательство "Перо"10.15829/2713-0177-2023-3-18endofocus-62Research ArticleСтатьиНГЛТ 1 типа как терапевтическая мишень при сахарном диабете 2 типа. Основы патофизиологии и функциональных возможностей в свете доказательных фактовThe sodium-glucose cotransporter isoform 1 as a target for influence in type 2 diabetes: basic physiology and functional properties in the light of evidence-based factshttps://orcid.org/0000-0002-6826-5924ТепловаА. С.TeplovaA. S.

ассистент кафедры эндокринологии лечебного факультета

117997, Москва, ул. Островитянова, д.1 

 

Anna S. Teplova – Assistant, Department of Endocrinology 

117997, Moscow, st. Ostrovityanova, 1 

anna_kochina_@mail.ruhttps://orcid.org/0000-0002-2552-5028ИброхимовХ. Х.IbrokhimovKh. Kh.

клинический ординатор

117997, Москва, ул. Островитянова, д.1 

 

Khudoyberdi Kh. Ibrokhimov – resident, Department of Endocrinology 

117997, Moscow, st. Ostrovityanova, 1 

khudoyberdi.ibrokhimov@mail.ruhttps://orcid.org/0009-0004-5242-2181ЭрдынееваА. С.ErdyneevaA. S.

 клинический ординатор 

117997, Москва, ул. Островитянова, д.1 

 

AyanaS. Erdyneeva – resident, Department of Endocrinology 

117997, Moscow, st. Ostrovityanova, 1 

ayana0599@mail.ruhttps://orcid.org/0000-0001-6385-540XДемидоваТ. Ю.DemidovaT. Y.

д.м.н., профессор, зав. кафедрой эндокринологии 

117997, Москва, ул. Островитянова, д.1 

Tatiana Y. Demidova – Doctor of Medical Sciences, Professor, Head. Department of Endocrinology 

117997, Moscow, st. Ostrovityanova, 1 

t.y.demidova@gmail.comФГАОУ ВО “Российский национальный исследовательский медицинский университет имени Н.И. Пирогова” Минздрава РоссииFederal State Autonomous Educational Institution of Higher Education «N.I. Pirogov Russian National Research Medical University» of the Ministry of Health of the Russian Federation20231812202343Гастроэндокринология6973Copyright © Теплова А.С., Иброхимов Х.Х., Эрдынеева А.С., Демидова Т.Ю., 20242024Теплова А.С., Иброхимов Х.Х., Эрдынеева А.С., Демидова Т.Ю.Teplova A.S., Ibrokhimov K.K., Erdyneeva A.S., Demidova T.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://endofocus.elpub.ru/jour/article/view/62

Из многочисленных исследований известно о роли ингибиторов НГЛТ-2 в снижении гликемии, а также о кардио- и нефропротекции у пациентов с сахарным диабетом 2 типа (СД2). Несколько меньше изучен НГЛТ 1 типа, управление и активность которого также может быть ключом к компенсации СД2, хронических заболеваний сердца, почек и других органов и тканей. На данный момент ингибирование НГЛТ-1 у людей может быть достигнуто только применением комбинированных ингибиторов НГЛТ-1/НГЛТ-2. Препараты с селективным ингибированием НГЛТ-1 активно изучаются на животных и в исследованиях in vitro. Настоящий обзор посвящен принципам действия НГЛТ-1, влиянию ингибирования НГЛТ-1 на патологические состояния, а также оценке перспективы применения иНГЛТ-1 у людей.

From numerous studies, it is known about the role of SGLT-2 inhibitors in reducing glycemia, cardio- and nephroprotection in patients with type 2 diabetes (DM2). SGLT-1 has been studied less, the management and activity of which may also be the key to compensation of type 2 diabetes, chronic diseases of the heart, kidneys and other organs and tissues. At the moment, inhibition of SGLT-1 in humans can only be achieved by using combined inhibitors of SGLT-1/SGLT-2. Drugs with selective inhibition of SGLT-1 are actively studied in animals and in vitro studies. This review is devoted to the principles of the action of SGLT-1, the effect of inhibition of SGLT-1 on pathological conditions, and also evaluation of the prospects for the use of SGLT-1i in humans.

ингибиторы натрий-глюкозного транспортера 1 типаингибиторы натрий глюкозного ко-транспортера 2 типасахарный диабет 2 типаканаглифлозинtype 1 sodium-glucose transporter inhibitorstype 2 sodium glucose transporter inhibitorstype 2 diabetes mellituscanagliflozinReferencesSano R, Shinozaki Y, Ohta T. Sodium-glucose cotransporters: Functional properties and pharmaceutical potential. J Diabetes Investig. 2020 Jul; 11(4):770–782. https://doi.org/10.1111/jdi.13255.Sano R, Shinozaki Y, Ohta T. Sodium-glucose cotransporters: Functional properties and pharmaceutical potential. J Diabetes Investig. 2020 Jul; 11(4):770–782. https://doi.org/10.1111/jdi.13255.Numata S, McDermott JP, Sanchez G, Mitra A, Blanco G. The sodium-glucose cotransporter isoform 1 (SGLT-1) is important for sperm energetics, motility, and fertility. Biol Reprod. 2022 Jun 13;106(6):1206–1217. https://doi.org/10.1093/biolre/ioac052.Numata S, McDermott JP, Sanchez G, Mitra A, Blanco G. The sodium-glucose cotransporter isoform 1 (SGLT-1) is important for sperm energetics, motility, and fertility. Biol Reprod. 2022 Jun 13;106(6):1206–1217. https://doi.org/10.1093/biolre/ioac052.Zhao M, Li N, Zhou H. SGLT1: A Potential Drug Target for Cardiovascular Disease. Drug Des Devel Ther. 2023 Jul 6;17:2011–2023. https://doi.org/10.2147/DDDT.S418321.Zhao M, Li N, Zhou H. SGLT1: A Potential Drug Target for Cardiovascular Disease. Drug Des Devel Ther. 2023 Jul 6;17:2011–2023. https://doi.org/10.2147/DDDT.S418321.Dominguez Rieg J.D., Chirasani V., Koepsell H., et al. Regulation of intestinal SGLT1 by catestatin in hyperleptinemic type 2 diabetic mice. FASEB J. 2015;29: A970.9. https://doi.org/10.1038/labinvest.2015.129.Dominguez Rieg J.D., Chirasani V., Koepsell H., et al. Regulation of intestinal SGLT1 by catestatin in hyperleptinemic type 2 diabetic mice. FASEB J. 2015;29: A970.9. https://doi.org/10.1038/labinvest.2015.129.Lehmann, A., & Hornby, P. J. (2016). Intestinal SGLT1 in metabolic health and disease. American journal of physiology. Gastrointestinal and liver physiology, 310(11), G887–G898. https://doi.org/10.1152/ajpgi.00068.2016.Lehmann, A., & Hornby, P. J. (2016). Intestinal SGLT1 in metabolic health and disease. American journal of physiology. Gastrointestinal and liver physiology, 310(11), G887–G898. https://doi.org/10.1152/ajpgi.00068.2016.Cefalo CMA, Cinti F, Moffa S, Impronta F, Sorice GP, Mezza T, Pontecorvi A, Giaccari A. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Cardiovasc Diabetol. 2019 Feb 28;18(1):20. doi: 10.1186/s12933-019-0828-y.Cefalo CMA, Cinti F, Moffa S, Impronta F, Sorice GP, Mezza T, Pontecorvi A, Giaccari A. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Cardiovasc Diabetol. 2019 Feb 28;18(1):20. doi: 10.1186/s12933-019-0828-y.Suga T, Kikuchi O, Kobayashi M, Matsui S, Yokota-Hashimoto H, Wada E, Kohno D, Sasaki T, Takeuchi K, Kakizaki S, Yamada M, Kitamura T. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels. Mol Metab. 2019 Jan;19:1–12. doi: 10.1016/j.molmet.2018.10.009 https://doi.org/10.1016/j.molmet.2018.10.009.Suga T, Kikuchi O, Kobayashi M, Matsui S, Yokota-Hashimoto H, Wada E, Kohno D, Sasaki T, Takeuchi K, Kakizaki S, Yamada M, Kitamura T. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels. Mol Metab. 2019 Jan;19:1–12. doi: 10.1016/j.molmet.2018.10.009 https://doi.org/10.1016/j.molmet.2018.10.009.Bruckert C, Matsushita K, Mroueh A, et al. Empagliflozin prevents angiotensin II-induced hypertension related micro and macrovascular endothelial cell activation and diastolic dysfunction in rats despite persistent hypertension: role of endothelial SGLT1 and 2. Vascul Pharmacol. 2022;146:107095. https://doi.org/10.1016/j.vph.2022.107095.Bruckert C, Matsushita K, Mroueh A, et al. Empagliflozin prevents angiotensin II-induced hypertension related micro and macrovascular endothelial cell activation and diastolic dysfunction in rats despite persistent hypertension: role of endothelial SGLT1 and 2. Vascul Pharmacol. 2022;146:107095. https://doi.org/10.1016/j.vph.2022.107095.Rieg T, Vallon V. Development of SGLT1 and SGLT2 inhibitors. Diabetologia. 2018 Oct;61 (10):2079–2086. https://doi.org/10.1007/s00125–018–4654–7.Rieg T, Vallon V. Development of SGLT1 and SGLT2 inhibitors. Diabetologia. 2018 Oct;61 (10):2079–2086. https://doi.org/10.1007/s00125–018–4654–7.Ishida N, Saito M, Sato S, Koepsell H, Taira E, Hirose M. SGLT1 participates in the development of vascular cognitive impair-ment in a mouse model of small vessel disease. Neurosci Lett. 2020;727:134929 https://doi.org/10.1016/j.neulet.2020.134929.Ishida N, Saito M, Sato S, Koepsell H, Taira E, Hirose M. SGLT1 participates in the development of vascular cognitive impair-ment in a mouse model of small vessel disease. Neurosci Lett. 2020;727:134929 https://doi.org/10.1016/j.neulet.2020.134929.Ishida, N., Saito, M., Sato, S., Tezuka, Y., Sanbe, A., Taira, E., … & Hirose, M. (2021). Mizagliflozin, a selective sglt1 inhibitor, improves vascular cognitive impairment in a mouse model of small vessel disease. Pharmacology Research &Amp; Perspectives, 9(5). https://doi.org/10.1002/prp2.869.Ishida, N., Saito, M., Sato, S., Tezuka, Y., Sanbe, A., Taira, E., … & Hirose, M. (2021). Mizagliflozin, a selective sglt1 inhibitor, improves vascular cognitive impairment in a mouse model of small vessel disease. Pharmacology Research &Amp; Perspectives, 9(5). https://doi.org/10.1002/prp2.869.Шестакова М.В., Аметов А. С., Анциферов М. Б., Бардымова Т. П., Валеева Ф.В., Галстян Г.Р., et al. Канаглифлозин: от гликемического контроля до улучшения сердечно-сосудистого и почечного прогноза у пациентов с сахарным диабетом 2 типа. Резолюция совета экспертов. Сахарный диабет. 2021;24(5):479–486. https://doi.org/10.14341/DM12848.Шестакова М.В., Аметов А. С., Анциферов М. Б., Бардымова Т. П., Валеева Ф.В., Галстян Г.Р., et al. Канаглифлозин: от гликемического контроля до улучшения сердечно-сосудистого и почечного прогноза у пациентов с сахарным диабетом 2 типа. Резолюция совета экспертов. Сахарный диабет. 2021;24(5):479–486. https://doi.org/10.14341/DM12848.Bhatt D.L., Szarek M., Steg P.G., et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117–128. https://doi.org/10.1056/nejmoa2030183.Bhatt D.L., Szarek M., Steg P.G., et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117–128. https://doi.org/10.1056/nejmoa2030183.

The authors declare that there are no conflicts of interest present.